Yep. I don't doubt it. It's just not coming across in the announcements.
How can a phase 3 oncology pharma with very strong indications of also having therapeutic effect have a MC of less than 30M?
Answer - delays and poor communications.
Ann: Shareholder Update - Progress and Strategy, page-30
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
-0.005(2.78%) |
Mkt cap ! $85.12M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.5¢ | 17.5¢ | $59.53K | 337.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 518045 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 34777 | 2 |
View Market Depth
| Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |